Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotronik Prepares For Next Era Of Drug-Eluting Stents

Executive Summary

Biotronik is touting successful clinical trial results with its Orsiro sirolimus-eluting coronary stent while continuing to develop a resorbable stent.

You may also be interested in...



Abbott Gains CE Marks For New Tricuspid Device And Expanded Xience DES Indication

The next-generation TriClip G4 comes in more sizes than the original TriClip and features enhanced leaflet grasping features.

Start-Up Spotlight: Elixir Works To 'Uncage' The Coronary After Intervention

The company is sponsoring INFINITY SWEDEHEART, a randomized trial of its DynamX Bioadaptor, a unique metallic coronary artery implant that adapts to vessel physiology.

Biotronik’s Orsiro Stent Beats Abbott’s Xience In BIOSTEMI Trial

Acute ST-elevation myocardial infarction patients treated with Biotronik’s Orsiro biodegradable polymer sirolimus-eluting stent had a significantly lower rate of target vessel failure than patients treated with Abbott’s Xience durable polymer everolimus-eluting stent at the one-year follow-up in the BIOSTEMI trial.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT143814

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel